港股異動 | 先聲藥業(2096.HK)大漲近12% 今年有望新增超10項創新藥IND
格隆匯5月13日丨先聲藥業(2096.HK)大漲近12%,報9.65港元創近一個月新高,暫錄四連漲,區間漲幅超23%,總市值255億港元。山東省千佛山醫院上個月披露,先聲藥業的3CL口服小分子候選藥物SIM0417的I期臨牀研究已完成首例受試者給藥,預計SIM0417(SSD843)I期臨牀研究將在5月底前完成所有受試者給藥工作。據悉,SIM0417是一種針對新型冠狀病毒複製必須的關鍵蛋白酶3CL的口服小分子候選藥物。作為一家創新與研發驅動的製藥公司,先聲藥業的創新佈局不僅僅在熱門的新冠口服藥。近日,先聲藥業預計,僅在2022年就有望新增近10項含中美雙報的臨牀試驗申請(IND)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.